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Objectives: We sought to evaluate a moderate-potassium cardioplegic solution using adenosine and lidocaine as
the arresting and protecting cardioprotective combination in pediatric cardiac surgery.
Methods: One hundred thirty-four patients with congenital heart disease were randomly allocated to one of 3
groups according to the cardioplegia formula used: the high-potassium (HP) group (Kþ, 20 mmol/L), 46 patients;
the high-potassium adenosine–lidocaine (HPAL) group (Kþ, 20 mmol/L; adenosine, 0.7 mmol/L; and lidocaine,
0.7 mmol/L), 44 patients; and the moderate-potassium adenosine–lidocaine (MPAL) group (Kþ, 10 mmol/L;
adenosine, 0.7 mmol/L; and lidocaine, 0.7 mmol/L), 44 patients. Hemodynamic data during the operation and
postoperative data were recorded. Serum cardiac troponin I concentrations were examined at the time points
of before cardiopulmonary bypass and 1, 3, 6, 12, and 24 hours after aortic crossclamp removal.
Results:At the end of cardiopulmonary bypass and modified ultrafiltration, the systolic and pulse pressures of the
MPAL group were significantly increased compared with the respective values of the HP group. At the time
points of 1 to 12 hours after reperfusion, the levels of serum cardiac troponin I were significantly decreased in
the MPAL group compared with those in the HP and HPAL groups.
Conclusions: The MPAL cardioplegia formula was associated with better myocardial protective effects.Currently, the majority of cardiac surgery centers use a high-
potassium cardioplegic solution to arrest the heart during car-
diac operations. The concentration of potassium is typically
greater than 15 mmol/L.1 Yet some studies have demonstrated
that high-potassium cardioplegia can induce myocardial ionic
and metabolic imbalances during ischemia and myocardial
stunning, tissue edema, endothelial damage, free radical pro-
duction, and functional loss during reperfusion.2
An alternative approach to arresting the heart is to main-
tain the transmembrane electrical potential in a polarized
state,3 which locks the ion channels in a ‘‘closed’’ state.
Therefore ionic imbalances and subsequent consequences
are likely to be avoided.3 Adenosine triphosphate–sensitive
potassium channel–opening agents (eg, nicorandil and apri-
kalim) have been used to achieve polarized or hyperpolar-
ized arrest.2 However, potassium channel–opening agents
have been reported to increase postischemic arrhythmias
and myocardial oxygen demand on reperfusion and to pro-
duce profound systemic hypotension. For these reasons, hy-
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as the arresting agent has not been adopted as a clinical car-
dioplegic strategy.
The combination of adenosine and lidocaine is an alter-
native method to achieve polarized arrest.4 In 2004, Cor-
vera and colleagues4 reported the effects of normokalemic
adenosine–lidocaine (AL) cardioplegia on an isolated rat
heart perfusion model. The AL cardioplegia was based on
Krebs–Henseleit solution, which contained 0.2 mmol/L
adenosine and 5 mmol/L lidocaine and in which the potas-
sium concentration was 5.9 mmol/L. The theory underlying
the experiment was that this normokalemic AL cardioplegia
solution could arrest the heart and meanwhile maintain the
myocardial cell membrane potential at the normal level
(about83 mV), which might avoid ion-channel activation
and extra energy consumption and in turn might improve
a protective effect. In 2005, Corvera and associates5
reported their in vivo experimental study on a canine car-
diopulmonary bypass (CPB) model, which demonstrated
that the myocardial protective effects of warm or cold AL
blood cardioplegia were equivalent to those of hypothermic
potassium blood cardioplegia. The aim of this study was to
investigate the cardioprotective effect of moderate-potas-
sium AL cardioplegia in the clinical setting of pediatric car-
diac surgery.
MATERIALS AND METHODS
The study was performed according to the Declaration of Helsinki (re-
vised version of Somerset West, Republic of South Africa, 1996) and all
relevant Chinese laws. The study protocol was approved by the ethics
committee of Xijing Hospital. All subjects provided written informed con-
sent before inclusion in the study.rgery c December 2008
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PAbbreviations and Acronyms
AL ¼ adenosine–lidocaine
CPB ¼ cardiopulmonary bypass
cTnI ¼ cardiac troponin I
HP ¼ high potassium
HPAL ¼ high-potassium adenosine–lidocaine
ICU ¼ intensive care unit
MPAL ¼ moderate-potassium adenosine–lidocaine
MUF ¼ modified ultrafiltration
PRBC ¼ packed red blood cell
Composition of Cardioplegic Solutions
The basic cardioplegic solution was supplied by the clinical pharmacy of
Xijing Hospital; 10%KCl solution, 2% lidocaine solution, and 0.3% aden-
osine solution were added before use by the perfusionist to achieve the var-
ious cardioplegic formulas. The compositions of the cardioplegic solutions
are as follows:
 high-potassium (HP) cardioplegia: Naþ, 117 mmol/L; Kþ, 20.0 mmol/L;
Mgþþ, 16 mmol/L; Caþþ, 1.2 mmol/L; HCO3
, 25 mmol/L, Cl, 140 mmol/
L; glucose, 10 mmol/L; pH 7.48;
 high-potassium AL (HPAL) cardioplegia: Naþ, 117 mmol/L; Kþ, 20.0
mmol/L; Mgþþ, 16 mmol/L; Caþþ, 1.2 mmol/L; HCO3
, 25 mmol/L;
Cl, 140 mmol/L; glucose, 10 mmol/L; lidocaine, 0.7 mmol/L; adeno-
sine, 0.7 mmol/L; pH 7.48; and
 moderate-potassium AL (MPAL) cardioplegia: Naþ, 117 mmol/L; Kþ,
10.0 mmol/L; Mgþþ, 16 mmol/L; Caþþ, 1.2 mmol/L; HCO3
, 25 mmol/
L; Cl, 140 mmol/L; glucose, 10 mmol/L; lidocaine, 0.7 mmol/L; aden-
osine, 0.7 mmol/L; pH 7.48.
Experimental Design
We performed a prospective, single-center, randomized controlled study.
After patients provided informed consent, they were randomly allocated
either to the HP cardioplegia group, the HPAL cardioplegia group, or the
MPAL cardioplegia group. The randomization was realized by messages
sealed in envelopes passed to the perfusionist just before the operation,
with the surgeons and intensive care physicians being unaware of the
allocation.
Study Population
Patients given diagnoses of congenital heart disease for which a clinical
decision was made to treat with a cardiac operation were eligible for enroll-
ment. Patients who were cocommitted with other systemic diseases or reop-
eration or had undergone right or left ventricular incision were not included.
One hundred thirty-four patients who were admitted in the institute of car-
diovascular surgery, Xijing Hospital, between March 1, 2007, and May 31,
2007, were included in the present study. Table 1 summarizes the primary
characteristics of the study population. There were no significant differences
among the 3 groups with regard to age, sex, and body weight or defect types.
The ratio of concomitant pulmonary hypertension among the 3 groups was
also comparable, which indicated that the randomized allocation of the
patients into 3 study groups was successful.
Anesthesia, CPB, and Surgical Intervention
Anesthesia, CPB, and surgical intervention were performed by the same
group of cardiac surgeons, perfusionists, and anesthetists. Anesthesia was
induced and maintained with intravenous propofol (target-controlled infu-
sion), sufentanil citrate, and atracurium. Patients’ blood was heparinizedThe Journal of Thoracic and Cabefore CPB with 300 IU/kg heparin, and the activated clotting time was
maintained during CPB at a value greater than 480 seconds by using kaolin
as the activating agent (ACT II HemoTec; Medtronic, Rueil Malmaison,
France), with additional doses of heparin, as required. The CPB was set
up with aortic cannulation and superior and inferior vena caval cannula-
tion. The extracorporeal circuit was primed with various amounts of a bal-
anced acetate solution containing 5% albumin, 0.5 g/kg mannitol, 2500 U
of heparin, and 1 3 106 KIU aprotinin. Packed red blood cells (PRBCs)
were added to the priming solution to maintain the CPB hematocrit value
at approximately 0.25, and an appropriate volume of 5% NaHCO3 was
added to correct the pH of the priming solution to 7.35 to 7.40. No calcium
was added to the priming solution. A membrane oxygenator was used, and
the appropriate flows were obtained with a roller pump (Stockert Instru-
ments, Munich, Germany) during moderate hypothermia (esophageal tem-
perature, 25C–30C) to maintain the venous oxygen saturation between
65% and 75%. If needed, conventional hemofiltration was used or extra
PRBCs were added during the rewarming period of CPB to meet the oxy-
gen consumption, and extra fluid was removed with modified hemofiltra-
tion to increase the hematocrit value to 0.32 to 0.35 after discontinuation
of CPB. After discontinuation of CPB and modified hemofiltration, antico-
agulation was reversed with protamine sulfate. Hypothermic myocardial
protection was provided by aortic crossclamping and antegrade infusion
of ice-cold cardioplegic solution, as described above, in a single dose of
20 mL/kg over 2 minutes. The cardioplegic solution was aspirated by
means of vigorous suction at the coronary sinus to prevent its return into
the CPB circuit.
Postoperative Management
Routine continuous postoperative monitoring included surface electro-
cardiography, transcutaneous pulse oximetry, and systemic arterial pressure
measurement. Inotropic, chronotropic, and afterload-reducing agents were
used as clinically indicated. Volume infusions (usually PRBCs or 5% albu-
min) were administered to maintain adequate filling pressures with systolic
perfusion pressures. Diuretics (usually furosemide, 1-2 mg $ kg1 per dose)
TABLE 1. Characteristics and congenital heart defect distributions
among the 3 groups
HP group
(n ¼ 46)
HPAL group
(n ¼ 44)
MPAL group
(n ¼ 44)
P
value
Sex, F/M 12/34 18/26 16/28 NS
Age, mo 23.3  2.8 25.1  2.9 24.2  3.2 .911
Body weight, kg 10.0  0.6 10.0  0.5 9.9  0.5 .992
Diagnosis, n
ASD 0 6 0
CAVCD 0 2 0
MI 2 0 0
PAVCD 2 0 2
TAPVCþASD 2 0 4
VSD 40 36 38 NS
VSD 30 30 26
VSDþAI 2 0 0
VSDþASD 2 6 6
VSDþMI 4 0 2
VSDþPDA 2 0 4
Concomitant PH 28 26 24 NS
HP, High potassium; HPAL, high potassium adenosine–lidocaine; MPAL, moderate-
potassium adenosine–lidocaine; ASD, atrial septal defect; CAVCD, complete atrial
ventricle canal defect; MI, mitral valve insufficiency; PAVCD, partial atrial ventricle
canal defect; TAPVC, total anomalous pulmonary vein connection; VSD, ventricular
septal defect; AI, aortic valve insufficiency; PDA, patent ductus arteriosus; PH, pulmo-
nary arterial hypertension.rdiovascular Surgery c Volume 136, Number 6 1451
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Pwere begun on the first postoperative morning or earlier if the patient was
oliguric (<1 cm3 $ kg1 $ h1).
Measurement of Serum Cardiac Troponin I
Concentrations
For each patient, six 2-mL blood samples were taken: at the induction of
anesthesia and again 1, 3, 6, 12, and 24 hours after arrival in the intensive
care unit (ICU). The blood was transferred into dry glass tubes and stored
at 4C to 8C for clot formation before centrifugation. Serum separated af-
ter centrifugation was frozen at70C until assay. The serum cardiac tro-
ponin I (cTnI) concentration was measured in the Department of Clinical
Laboratory of our hospital in duplicate with an Access AccuTnI assay
(Beckman Coulter, Fullerton, Calif) system by individuals unaware of
the group allocation.
Data Collection
Preoperative and postoperative data were collected prospectively by
the study team from the day of surgical intervention until hospital dis-
charge. The preoperative data included age, sex, and body weight. The
operative data include CPB time; aortic crossclamp time; total volume
of cardioplegia; lowest temperature during CPB; hematocrit value before
the operation, during CPB, and at the end of the operation; total volume of
fluid output (ultrafiltration plus urine volume) during the operation; and
hemodynamic parameters, including blood pressure data before the start
of CPB, after the discontinuation of CPB, and at the end of modified ul-
trafiltration (MUF). The postoperative data included the number of hours
of mechanical ventilation in the ICU, the number of days in the ICU, total
volume of blood transfusion, total volume of chest drainage, and length of
hospitalization after the operation. Any complications after the operation
were also recorded. Serial data, such as serum cTnI concentration at dif-
ferent time points, were measured as described above. The inotrope
scores6,7,8 at different time points in the ICU were calculated as dopamine
(31) plus dobutamine (31) plus amrinone (31) plus milrinone (315)
plus epinephrine (3100) plus norepinephrine (3100) plus isoprenaline
(3100).
Statistical Analyses
All continuous variables are expressed as means  standard error of the
mean, whereas discrete variables are presented as frequencies and percent-
ages. Analyses of categorical variables were performed with the c2 test.
Analysis of continuous variables was performed with a 2-way analysis of
variance, and multiple comparisons were made with post hoc least-signifi-
cant-difference comparisons.1452 The Journal of Thoracic and Cardiovascular SRESULTS
Overall Clinical Results and Safety Evaluation
All 3 cardioplegic solutions quickly arrested hearts within
2 minutes. There were no significant mechanical or electrical
activities during the intracardiac operative period for all 3
groups. All the patients resumed spontaneous rhythm on aortic
crossclamp removal, and there was no temporary pacing
needed for any hearts. There were no deaths; no dialysis was
necessitated because of renal failure, no cerebral impairment
occurred, and no mediastinal reexploration was required be-
cause of postoperative bleeding in any of the 3 groups. There
was a 6-month-old girl with ventricular septal defect and pul-
monary hypertension in the MPAL group who underwent car-
diopulmonary resuscitation and reintubation at the third
postoperative day caused by vomiting and pulmonary aspira-
tion. The resuscitation was successful, and the intubation was
removed on the 15th postoperative day. She was discharged
on the 24th postoperative day without any complications.
Comparison of Operative and Postoperative
Parameters
As indicated in Table 2, the preoperative and operative pa-
rameters among the 3 groups were comparable with regard
to aortic crossclamp time, CPB time, cardioplegia volume,
lowest body temperature during CPB, hematocrit value (be-
fore the operation, during CPB, and at the end of operation),
and fluid output during the operation.
The total mediastinal drainage volume and the first me-
chanical ventilation time were comparable among the 3
groups; the reintubation time for the child in the MPAL group
was not included in the statistical analysis. The ICU times of
the 3 groups were comparable (P ¼ .053). The postoperative
hospital times of the 3 groups were comparable (P ¼ .304).
Hemodynamic Changes During the Operation
Systolic and diastolic arterial pressures were recorded;
pulse pressures were calculated according to the followingTABLE 2. The operative and postoperative parameters of the 3 groups (mean ± SEM)
HP group (n ¼ 46) HPAL group (n ¼ 44) MPAL group (n ¼ 44) P value
Crossclamp time, min 40.6  3.0 37.9  2.7 38.8  3.0 .797
CPB time, min 66.7  3.6 66.9  3.3 66.9  3.8 .999
Volume of cardioplegia, mL 213  12 214  18 206  15 .921
Lowest body temperature, C 29.8  0.2 30.0  0.2 29.9  0.2 .790
Hematocrit,%
Preoperative 36.4  0.5 36.8  0.4 36.5  0.5 .841
During CPB 24.9  0.6 23.9  0.4 24.6  0.4 .347
End of operation 35.5  0.7 36.0  0.3 35.6  0.8 .807
Fluid output at end of operation, mL 483  40 460  39 465  22 .880
Mechanical ventilation time, h 10.6  1.5 9.3  0.7 11.3  1.0 .452
Total mediastinal drainage, mL 103  9 87  7 119  14 .111
ICU time, d 2.5  0.1 2.4  0.2 2.7  0.4 .053
Postoperative hospital time, d 12.7  1.1 11.8  0.6 11.1  1.4 .304
SEM, Standard error of the mean; HP, high potassium; HPAL, high potassium adenosine–lidocaine; MPAL, moderate-potassium adenosine–lidocaine; CPB, cardiopulmonary
bypass; ICU, intensive care unit.urgery c December 2008
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pressure.
As indicated in Table 3, these 3 parameters changed in the
same fashion, decreasing at the end of CPB and then increas-
ing at the end of MUF. They were similar before the start of
the CPB among the 3 groups. At the end of CPB, the systolic
and pulse pressures of the MPAL group were significantly
increased compared with the respective values of the HP
group (68  2.1 vs 62  1.5 mm Hg [P ¼ .013] and 29 
1.5 vs 25  0.9 mm Hg [P ¼ .029], respectively). At the
end of MUF, the systolic and pulse pressures of the
MPAL group were significantly increased compared with
the respective values of the HP group (81  1.7 vs 73 
1.6 mm Hg [P ¼ .001] and 36  0.9 vs 29  1.1 mm Hg
[P ¼ .000], respectively). At the end of MUF, the systolic
pressure of the HPAL group was increased compared with
that of the HP group (78  1.7 vs 73  1.6 mm Hg [P ¼
.030]), but the differences in pulse pressures between these
2 groups did not reach a statistically significant level (32
 1.1 vs 29  1.1 mm Hg [P ¼ .092]).
Serum cTnI Release
In the 3 groups the concentrations of serum cTnI before
the operation were at similarly low levels. They surged to
high levels after the removal of the aortic crossclamp,
reached their highest level 3 hours after reperfusion, and
then decreased in the same fashion but did not return to
the preoperative baseline at 24 hours after removal of the
aortic crossclamp (Table 4). However, at the time points
from 1 to 12 hours after reperfusion, levels of serum cTnI
were significantly decreased in the MPAL group compared
with those in the HP and HPAL groups.
Inotrope Score
We evaluated inotropic drug use according to the inotrope
scoring method previously used by our group, and there
were no significant differences among the 3 groups. It
seemed that the inotrope scores in the HP group were higher
than those in the HPAL and MPAL groups at the time points
of 1, 3, 6, 12, and 24 hours after ICU arrival, but analysis
showed that the differences did not reach a statistically sig-
nificant level (Table 5).DISCUSSION
Safety and Effectiveness
This clinical study compared the myocardial protective
effects of different potassium concentrations during AL
cardioplegia relative to classic high-potassium cardioplegia
during hypothermia in pediatric patients with congenital heart
defects. Because this was an explorative study, we enrolled
patients with relatively simple heart defects that could be re-
paired without prolonged CPB time and heart arrest time. All
3 cardioplegic formulas arrested hearts quickly within 2 min-
utes. There were no significant mechanical or electrical activ-
ities during the intracardiac operative period in all 3 groups.
There were no deaths, no dialyses necessitated by renal fail-
ure, no cerebral impairments, and no requirement for medias-
tinal reexploration caused by postoperative bleeding in the
TABLE 3. Hemodynamic changes during surgical intervention in the
3 groups (mean ± SEM)
HP group
(n ¼ 46)
HPAL group
(n ¼ 44)
MPAL group
(n ¼ 44)
P
value
Before CPB
Systolic pressure,
mm Hg
80  2.2 81  2.2 77  2.0 .370
Diastolic pressure,
mm Hg
48  1.5 49  1.7 47  1.6 .764
Pulse pressure,
mm Hg
32  1.6 33  1.0 30  1.4 .407
After CPB
Systolic pressure,
mm Hg
62  1.5 65  1.6 68  2.1* .034
Diastolic pressure,
mm Hg
37  1.2 39  1.1 40  1.7 .370
Pulse pressure,
mm Hg
25  0.9 26  1.0 29  1.5* .059
After MUF
Systolic pressure,
mm Hg
73  1.6 78  1.7* 81  1.7* .005
Diastolic pressure,
mm Hg
44  1.4 46  1.2 45  1.7 .486
Pulse pressure,
mm Hg
29  1.1 32  1.1 36  0.9* .000
SEM, Standard error of the mean; HP, high potassium; HPAL, high potassium aden-
osine–lidocaine; MPAL, moderate-potassium adenosine–lidocaine; CPB, cardiopul-
monary bypass; MUF, modified ultrafiltration. *Significantly increased compared
with the respective value in the HP group.TABLE 4. Serial perioperative serum cTnI concentrations (mean ± SEM)
HP group (n ¼ 46) HPAL group (n ¼ 44) MPAL group (n ¼ 44) P value
Before the operation 0.22  0.03 0.17  0.03 0.16  0.03 .262
One hour after reperfusion 48.94  9.60 28.86  2.70 18.32  2.79*y .002
Three hours after reperfusion 53.46  9.41 36.78  3.75 25.76  3.47*y .009
Six hours after reperfusion 34.61  4.40 36.21  3.80 21.97  3.08*y .018
Twelve hours post reperfusion 29.84  3.99 28.89  2.97 18.56  2.60*y .029
Twenty-four hours after reperfusion 20.33  2.79 19.59  2.29 13.72  2.16 .116
Values are presented in nanograms per milliliter. SEM, Standard error of the mean; HP, high-potassium; HPAL, high-potassium adenosine–lidocaine; MPAL, moderate-potassium
adenosine–lidocaine. *Significantly decreased compared with the respective value in the HP group. ySignificantly decreased compared with the respective value in the HPAL group.
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MPAL cardioplegia is safe and effective.
Correlation Between Cell Membrane Potential and
Potassium Concentration in Cardioplegia
The cell membrane potential (VM in millivolts) can be
calculated from the Nernstian distribution of Kþ ions be-
tween the extracellular and intracellular phases as follows4:
VM ¼ Ekþ RT
zKþF
3ln
½KþOUT
½KþIN
;
where R is the universal gas constant (8.31 J%2219 mol1 $
K1), F is Faraday’s constant (96.49 KJ $ mol1 $ V1), T is
absolute temperature (311.15 K), z is the valence of potas-
sium ion (þ1), and [Kþ]IN and [Kþ]OUT are the intracellular
and extracellular concentrations of Kþions in moles per liter,
respectively. [Kþ]IN was estimated to be a constant value of
about 88 to 89 mmol/L, and it was assumed that [Kþ]OUT was
equal to the potassium concentration in the HP and HPAL
cardioplegic formulas (20 mmol/L Kþ) and the MPAL cardi-
oplegic formula (10 mmol/L Kþ). The cell membrane poten-
tial was approximately 46 mV when the HP and HPAL
cardioplegic solutions were used and approximately 67
mV when the MPAL cardioplegic solution was used. Our
results support the hypothesis that a less depolarized cell
membrane during cardioplegic arrest is related to better
myocardial protection and less reperfusion injury. This
could be reflected by the better hemodynamic features dur-
ing the operation and the decreased cTnI release during
the early postreperfusion period in the MPAL group.
Mechanisms for MPAL Cardioplegia’s Superiority
Over HP Cardioplegia
The mechanisms for MPAL cardioplegia’s superiority
over HP cardioplegia were not investigated in the present
TABLE 5. Serial postoperative inotropic scale comparisons among the
3 groups (mean ± SEM)
HP group
(n ¼ 46)
HPAL group
(n ¼ 44)
MPAL group
(n ¼ 44)
P
value
One hour after ICU
arrival
3.8  0.5 2.7  0.4 2.6  0.2 .053
Three hours after ICU
arrival
3.8  0.5 2.8  0.4 2.7  0.2 .085
Six hours after ICU
arrival
3.8  0.5 2.8  0.5 2.7  0.2 .103
Twelve hours after
ICU arrival
3.7  0.5 2.8  0.5 2.7  0.2 .145
Twenty-four hours
after ICU arrival
3.3  0.4 2.7  0.4 2.3  0.3 .194
Forty-eight hours after
ICU arrival
2.0  0.4 2.5  0.4 1.4  0.3 .081
SEM, Standard error of the mean; HP, high-potassium; HPAL, high-potassium aden-
osine–lidocaine; MPAL, moderate-potassium adenosine–lidocaine; ICU, intensive
care unit.1454 The Journal of Thoracic and Cardiovascular Sstudy but have previously been extensively discussed by
Dobson.6 We summarize the main points as follows.
First, combined use of adenosine and lidocaine is related
to better preservation of adenosine triphosphate, phospho-
creatine, and glycogen stores and maintenance of a high cy-
tosolic phosphorylation ratio during arrest, ischemia, and
reperfusion.
Second, adenosine activates the A1 receptor subtype to
exhibit its negative chronotropy, negative dromotropy, and
negative inotropy, which contribute to arresting the heart.
Furthermore, A1 receptor activation has been linked to the
opening of the sarcolemmal adenosine triphosphate–sensi-
tive Kþchannel, stabilization of mitochondria mitochondrial
permeability transition pore, and inhibition of the stimula-
tory effects of catecholamines.
Third, Lidocaine can block cardiomyocyte fast Naþchan-
nels and effectively clamp the cell membrane near its resting
membrane potential. Because fewer ion channels or pumps
are activated at polarized potentials, the drug might reduce
energy-sparing effects.
Fourth, because of fast Naþ-channel blockade, the lido-
caine and adenosine combination might further reduce Naþ
and Caþþ loading.
Fifth, superior arrest and protection might also relate to
the coronary vasodilatory properties of adenosine, lido-
caine, and low potassium concentration, which result in
reduced coronary vascular resistance and greater delivery
of cardioplegia. This had been confirmed by the study of
Dobson.4
Sixth, concentrations of potassium of greater than 15
mmol/L have been linked to left ventricular dysfunction
and endothelial damage, and these deleterious effects are
concentration dependent. Our results support these experi-
mental studies and show that MPAL cardioplegia is linked
with better hemodynamic features, including higher systolic
pressures and pulse pressures at the end of CPB and MUF
compared with the HP and HPAL groups.
Limitations of the Study
One of the limitations of this study was that the patients
included in the study were all committed with simple
congenital heart defects without cyanosis, and therefore
the significance of the results might be very limited. An-
other limitation of this study was that we used systolic
and pulse pressures to evaluate the hemodynamic perfor-
mances of different groups. Because the pressure measure-
ments were load dependent, this somewhat impaired their
significance as perfect parameters of heart functions during
the operation. Considering this was a controlled, blind, and
randomized study, the pressure measurements still had
some values to reflect the hemodynamic differences. The
most important limitation of this study was that the cardio-
plegic formula we used was not a normokalemic one,
which is somewhat different from Dobson’s studies.urgery c December 2008
Jin et al Cardiopulmonary Support and Physiology
C
S
PA normokalemic cardioplegic solution might be better than
the MPAL solution we used here, and the newest evidence
from Dobson’s laboratory9 showed that normokalemic AL
cardioplegia could be delivered intermittently or continu-
ously with similar functional recoveries after a 40- or 60-
minute arrest at 33C in an isolated, perfused rat heart
model. For safety reasons, we did not try the normal-potas-
sium AL formula in a clinical setting. Corvera and associ-
ates5 demonstrated that intermittent polarized arrest with
warm or cold AL blood cardioplegia provided the same
degree of myocardial protection as intermittent hypother-
mic Kþblood cardioplegia in a canine CPB model, but
the AL solution did not show any superiority to traditional
hyperkalemic cardioplegia. Whether normal-potassium AL
cardioplegia is as safe and effective as MPAL cardioplegia
in a clinical setting requires more experimental investiga-
tion.
CONCLUSION
The combined use of adenosine and lidocaine in a moder-
ate-potassium cardioplegic formula resulted in better myo-
cardial protection.The Journal of Thoracic and CWe thank Ying Yang for her excellent assistance in cardiomyo-
cyte membrane potential calculation.
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